Smart immune cells take aim at tough blood cancers
NCT ID NCT06325748
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new therapy called SENTI-202, which uses specially designed immune cells (CAR NK cells) to find and attack cancer cells in people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The cells are 'off-the-shelf,' meaning they are made in a lab and ready to use without needing to be made from each patient's own cells. The study involves 21 participants and focuses on safety, dosing, and how well the therapy works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SENTI-202 (a type of immune cell therapy called CAR NK cells)
- What this could lead to
- If successful, this could point toward a new treatment option for people with hard-to-treat blood cancers like AML and MDS, using ready-made immune cells that target cancer while sparing healthy cells.
- What could go wrong
- This is a very early (Phase 1) and small trial (21 people), so safety and dosing are the main focus. The therapy may not work or could cause serious side effects, and it's too soon to know if it will help patients long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML/MDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Methodist Healthcare
San Antonio, Texas, 78229, United States
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
TriStar Bone Marrow Transplant
Nashville, Tennessee, 37203, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells stop blood cancer relapse?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can donor immune cells tame stem cell transplant risks?
- Can a poison become a cure? arsenic trioxide put to the test in blood cancer transplant
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?